## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ara-290`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ara-290/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ara-290/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ara-290/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ara-290` v40 · content_hash `d45c36708ae8b171…` · thread_head genesis · 32 DIVs
- **thesis (c1):** ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.
  - c2 [mechanistic/active] Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding 
  - c3 [mechanistic/active] The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.
  - c4 [human/active] In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom s
  - c5 [human/active] In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an o
  - c6 [human/active] In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.
  - c7 [preclinical/active] In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory 
  - c8 [preclinical/active] ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ara-290/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ara-290/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ara-290`
- **title:** ARA-290 (Cibinetide)
- **url:** https://miscsubjects.com/a/ara-290
- **register:** essay
- **updated:** 2026-07-24T17:41:58.206Z
- **tags:** peptide, ara-290, cibinetide, neuropathy, disc

## Body

ARA-290, also called cibinetide, is an 11-amino-acid peptide cut from a single face of the erythropoietin molecule. It keeps EPO's tissue-repair signal and throws away EPO's blood-building one — and that split is the entire point of the drug. It is the rarest and, in one specific way, the best-evidenced compound in a disc-recovery stack: unlike the others, it has randomized, placebo-controlled human trials, and some of that data shows nerves physically regrowing. It is also the hardest to actually obtain, and its developer has effectively gone dark. This page covers the mechanism, the human and preclinical evidence graded honestly, the exact trial dosing, the safety story (which is EPO's story inverted), the sourcing reality, and precisely where it fits for the nerve pain of a damaged disc. No prior knowledge assumed.

## Erythropoietin, minus the blood

EPO is famous for telling the marrow to make red blood cells, and infamous for the clots and strokes that follow when athletes abuse it. But EPO does something else at a site of injury: it protects and repairs stressed tissue. The problem is you cannot dose EPO for repair without also thickening the blood and taking on that risk.

Michael Brines and Anthony Cerami worked out why the two effects separate. EPO's repair signal runs through a different receptor than its blood signal — a heterocomplex of the EPO receptor joined to the beta-common receptor, which they named the innate repair receptor.

[[embed:source:s8]]

Once repair was known to run through a distinct receptor, they built small peptides mimicking only the repair-active face of EPO. ARA-290 is that idea shipped as an 11-amino-acid drug.

[[embed:source:s9]]

## The receptor that only shows up when tissue is hurt

The innate repair receptor is not sitting on healthy cells. It is upregulated on injured and inflamed tissue — so ARA-290 acts where there is damage and stays quiet where there isn't. Its job there is anti-inflammatory and pro-survival: it tells macrophages to stand down and keeps stressed cells alive.

[[embed:source:s6]]

## It regrows nerve fibers — measured, not felt

This is what separates ARA-290 from nearly everything else marketed as a healing peptide. In a Phase 2b randomized controlled trial in 64 patients with sarcoidosis-associated small-fiber neuropathy, 4 mg/day cibinetide significantly increased corneal nerve fiber area — an objective, imaged measure — and raised GAP-43-positive regenerating fibers in the skin. GAP-43 marks nerves actively growing back.

[[embed:source:s3]]

An earlier randomized, double-blind pilot had already shown the symptom side: significantly better neuropathy scores versus placebo by week four.

[[embed:source:s1]]

The independent read was blunt: it regenerates nerve fibers.

[[embed:source:s12]]

## It calms the nerve, not just the symptom

This is why it matters for a disc. Radicular pain — sciatica — is not only mechanical; when nucleus pulposus contacts a nerve root it sets off neuroinflammation, much of it driven by activated microglia in the spinal cord. In nerve-injury models, ARA-290 produced long-lasting, dose-dependent reductions in allodynia that tracked with suppression of exactly that spinal microglial response.

[[embed:source:s5]]

So the mechanism is not "mask the pain for a few hours." It is "quiet the central inflammation generating the pain" — a more durable kind of relief, aimed at the specific way a herniated disc hurts.

## The benefit generalizes past nerves

The repair signal is not nerve-specific. The same peptide class is anti-apoptotic and tissue-protective in the heart.

[[embed:source:s7]]

And a second human population — type 2 diabetics — showed improved neuropathic symptoms alongside better HbA1c and lipids over 56 days, with no safety signal.

[[embed:source:s4]]

Two independent human neuropathy datasets plus organ-level tissue protection in the lab is a stronger evidence base than most peptides in this category can claim.

## How it's dosed

The human trials are specific and consistent, which is unusual here.

- **Dose:** 4 mg subcutaneously, once daily, is the effective and consensus clinical dose. The dose-ranging trial tested 1, 4, and 8 mg; 4 mg was the sweet spot.
- **Duration:** trials ran 28 days, with follow-up out to weeks; symptom and structural nerve changes were measurable by day 28.
- **The half-life paradox:** ARA-290 clears the blood in minutes, yet is dosed once daily and works. It triggers a downstream repair program rather than needing sustained blood levels, so the effect outlasts the drug by 24-72 hours. This is why a minutes-long half-life and once-daily dosing are not a contradiction.

## The safety story is EPO's, inverted

The single most important safety fact: because ARA-290 works through the innate repair receptor and not the classic EPO receptor, it does not stimulate red-cell production or raise hematocrit — confirmed in the trials, with no change in hemoglobin, hematocrit, or reticulocytes.

[[embed:source:s11]]

That removes the clotting hazard that makes EPO dangerous and is the reason chronic dosing for repair is even conceivable. Across the Phase 2 trials the only adverse events were mild, transient injection-site reactions; no serious drug-related events. The honest limit: total human exposure is small (under ~200 patients, all ≤28 days), so long-term safety is uncharacterized, and as an innate-repair-receptor agonist it should be treated cautiously in active malignancy.

## You probably can't get the real thing

This is the practical catch. ARA-290 was developed by Araim Pharmaceuticals, earned FDA Orphan Drug and Fast Track designations for sarcoidosis neuropathic pain plus EU orphan status, met its Phase 2b endpoint — and then stalled. No Phase 3 was completed, it is not approved for anything, and as of 2026 Araim has effectively ceased operations with no active trials registered. So there is no pharmaceutical supply. On the grey market it is far rarer and costlier than BPC-157 or TB-500, carried by few vendors intermittently, which means less independent testing and higher odds of an underdosed or degraded 11-amino-acid peptide. If someone sources it, a third-party HPLC-plus-mass-spec certificate per batch is non-negotiable.

## What people report

Controlled trials are the evidence; user accounts are color. One first-person write-up describes going from weeks of stabbing nerve pain to none on ARA-290.

[[embed:source:s13]]

A single uncontrolled anecdote, weighed far below the randomized data — but it rhymes with what the trials measured.

## Where it fits for the spine

In a disc-recovery stack the division of labor is clean. BPC-157 and TB-500 target the tissue — annulus, ligament, surrounding soft tissue. Retatrutide targets mechanical load. ARA-290 targets the nerve: it is the arm for the neuroinflammatory, radicular pain of a herniation, and the only one of the four with human evidence of actual nerve regeneration. The inflamed nerve root of a herniated disc is, mechanistically, exactly the small-fiber, neuroinflammatory target ARA-290 was built for — even though no one has run it against discs. The framework is in the disc-stack, herniated-disc, and degenerative-disc-disease pages.

## Proven, unproven, unknown

Proven in humans: ARA-290 reduces neuropathic-pain symptoms and increases measurable nerve-fiber regrowth in sarcoidosis small-fiber neuropathy, and improves diabetic neuropathic symptoms — in randomized, placebo-controlled trials, without raising hematocrit. Unproven: that this translates to the radicular pain of a herniated disc; that step is mechanistic reasoning plus adjacent trial data, not a disc trial. Unknown: long-term safety, and — practically — whether the vial you can actually buy contains the real peptide.

*Not medical advice. ARA-290 is investigational, not approved for any condition, and has no pharmaceutical supply. Nothing here is a dosing or treatment recommendation.*


## Claims (10)

- **c4** [human w=?] In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.
  - sources: s1
- **c5** [human w=?] In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.
  - sources: s3, s2, s12
- **c6** [human w=?] In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.
  - sources: s4
- **c7** [preclinical w=?] In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.
  - sources: s5
- **c8** [preclinical w=?] ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.
  - sources: s6
- **c9** [preclinical w=?] The helix-B-surface peptide class (ARA-290) is anti-apoptotic and tissue-protective across organs, including the heart, indicating a general repair mechanism.
  - sources: s7, s9
- **c1** [mechanistic w=?] ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.
  - sources: s8, s9, s11
- **c2** [mechanistic w=?] Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.
  - sources: s11, s4
- **c3** [mechanistic w=?] The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.
  - sources: s8, s9
- **c10** [anecdotal w=?] Uncontrolled first-person reports describe rapid relief of stabbing nerve pain on ARA-290, consistent with but far weaker than the controlled trial data.
  - sources: s13

## Voxel graph (10 atoms · 17 edges)
- full graph: https://miscsubjects.com/api/articles/ara-290/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (13)
- chain valid: no · head: ``

### s1 · pubmed
- title: Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
- url: https://pubmed.ncbi.nlm.nih.gov/23168581/
- quote: The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo
- claim_ids: c4
- hash: ``

### s2 · pubmed
- title: Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis
- url: https://clinicaltrials.gov/study/NCT02039687
- quote: activate repair mechanisms and accelerate healing, including the nerve damage that can be associated with sarcoidosis
- claim_ids: c5
- hash: ``

### s3 · pubmed
- title: Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain
- url: https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/
- quote: The placebo-corrected mean change from baseline CNFA at day 28 was 697 (159, 1236; P = 0.012)
- claim_ids: c5
- hash: ``

### s4 · pubmed
- title: ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- url: https://pubmed.ncbi.nlm.nih.gov/25387363/
- quote: Subjects receiving ARA 290 exhibited an improvement in hemoglobin A1c and lipid profiles throughout the 56 d observation period.
- claim_ids: c6
- hash: ``

### s5 · pubmed
- title: ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/
- quote: ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response
- claim_ids: c7
- hash: ``

### s6 · pubmed
- title: A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
- url: https://pubmed.ncbi.nlm.nih.gov/26683514/
- quote: Secretion of pro-inflammatory cytokines (IL-6, IL-12, and TNF-alpha) from macrophages was significantly inhibited by ARA 290.
- claim_ids: c8
- hash: ``

### s7 · pubmed
- title: Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin
- url: https://pubmed.ncbi.nlm.nih.gov/20660739/
- quote: HBSP protects cardiomyocytes from apoptosis and leads to a favorable outcome in failing hearts
- claim_ids: c9
- hash: ``

### s8 · pubmed
- title: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor
- url: https://pubmed.ncbi.nlm.nih.gov/15456912/
- quote: EpoR and betacR comprise a tissue-protective heteroreceptor.
- claim_ids: c1, c3
- hash: ``

### s9 · pubmed
- title: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
- url: https://pubmed.ncbi.nlm.nih.gov/18676614/
- quote: the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure.
- claim_ids: c1, c3
- hash: ``

### s11 · news
- title: ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor
- url: https://superpower.com/guides/ara-290
- quote: not stimulate erythropoiesis or raise red blood cell counts
- claim_ids: c2
- hash: ``

### s12 · news
- title: Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients
- url: https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/
- quote: cibinetide (ARA 290) was shown to promote significant corneal nerve and improve pain and functional capacity in a clinical trial with sarcoidosis patients.
- claim_ids: c5
- hash: ``

### s13 · news
- title: ARA 290 for Nerve Pain & Regeneration (first-person account)
- url: https://diaryofrecovery.com/ara/
- quote: I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain.
- claim_ids: c10
- hash: ``

### s14 · news
- title: Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis)
- url: https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html
- quote: Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis
- hash: ``

## Provenance (36 model passes)
- chain valid: yes · head: `ca265fdc896bfe14`

- sources · grok-4.3 · 2026-06-29T17:15 · hash `54e9f759bd90`
- sources · grok-4.3 · 2026-06-29T17:15 · hash `87b2ba9de5f0`
- sources · grok-4.3 · 2026-06-29T17:16 · hash `48459e1de6a6`
- repair · repair · 2026-06-29T19:11 · hash `5e01d4ed16b8`
- repair · repair · 2026-06-29T19:20 · hash `4314fcff1e2c`
- claim · fill-slots · 2026-06-29T20:25 · hash `347711c6c032`
- claim · fill-slots · 2026-06-29T20:25 · hash `dd2d9c47ef9b`
- voxel_divide · owner · 2026-07-17T02:38 · hash `ca265fdc896b`

## Question graph
- questions: 8 · evidence ingests: 3
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No imaging-confirmed outcomes; no long-term follow-up; no interaction data specific to herniated-disc patients or common spine medications.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: No controlled human trials for herniated-disc outcomes; No data on BPC-157/TB-500 interactions or safety in disc pathology; No coverage of other peptides (e.g., ARA-290) for herniated discs in the provided slugs
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No controlled human data for herniated discs; anecdotes are n=1, self-reported, no imaging follow-up.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: no human controlled data for disc herniation; no interaction data; no ARA-290 or TB-500 herniated-disc coverage in topology; long-term safety absent
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6** [gap] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No human imaging follow-up data; No controlled trials for disc herniation; Long-term safety unknown
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9** [gap] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: no human disc-herniation trials; no established stacks for herniated discs; no long-term safety data; no interaction data
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c** [gap] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No dosing, duration, route, or imaging-confirmed outcomes are stated; long-term safety unknown (bpc-157:c67).
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f** [gap] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: no human disc-healing studies; no stack protocols in topology; no interaction data; no long-term safety data; anecdotes are n=1 only

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ara-290/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ara-290/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ara-290","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ara-290|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ara-290|tier|assertion`
- **iMessage ask:** `ara-290|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ara-290`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*